10月26日 - 药物开发商Aspen Neuroscience和Bambusa Therapeutics周一启动了美国首次公开募股（IPO）路演，加入了生物技术行业利用秋季IPO窗口期上市的浪潮。
Oct 26 - Drug developers Aspen Neuroscience and Bambusa Therapeutics launched their US initial public offering roadshows on Monday, adding to a wave of issuers from the biotech industry that have tapped the fall IPO window.
在今年原本低迷的秋季IPO窗口期中，该行业成为一大亮点，因为不断上升的借贷成本和动荡的市场状况抑制了其他行业的活动。
The sector has been a bright spot in an otherwise lackluster fall IPO window this year, as rising borrowing costs and choppy market conditions keep a lid on activity from other industries.
自9月以来，已有半打多生物技术公司在纽约上市。药物开发商Rezera和Windward Bio上周也披露了美国IPO招股文件，这是启动潜在路演前的关键步骤。
More than half a dozen biotech firms have gone public in New York since September. Drug developers Rezera and Windward Bio also unveiled their US IPO filings last week, a key step ahead of a potential roadshow launch.
IPOX助理Lukas Muehlbauer对路透社表示：“生物技术为投资者提供了机会，临床催化剂即使在宏观经济前景不确定时也能推动回报，给了专业投资者理由在利率较高的情况下支持个别公司。”
"Biotech offers investors opportunities where clinical catalysts can drive returns even when the broader economic outlook is uncertain, giving specialist investors reasons to back individual companies despite higher rates," IPOX associate Lukas Muehlbauer told Reuters.
“近期一些上市项目的强劲首秀也有助于鼓励下一批发行人，特别是那些为即将到来的试验寻求资金的公司。不过，投资者胃口依然具有选择性，因为较高的融资成本仍是那些可能数年无法产生收入的公司面临的挑战。”
"Strong debuts from some recent listings also helps to encourage the next group of issuers, particularly those seeking funding for upcoming trials. Still, investor appetite remains selective, as higher financing costs remain a challenge for companies that may be years away from generating revenue."
总部位于加利福尼亚州圣地亚哥的Aspen正在开发神经退行性疾病疗法。其首款候选产品sasineprocel正处于治疗帕金森病的早期至中期临床试验阶段。
San Diego, California-based Aspen is developing therapies for neurodegenerative diseases. Its lead product candidate, sasineprocel, is in an early-to-mid-stage trial to treat Parkinson’s disease.
总部位于马萨诸塞州波士顿的Bambusa正在开发治疗免疫和炎症性疾病的药物。其首款候选产品BBT001正处于治疗一种皮炎及其他炎症性皮肤病的早期开发阶段。
Boston, Massachusetts-based Bambusa is developing drugs for immunological and inflammatory disorders. Its lead product candidate, BBT001, is in early-stage development to treat a type of dermatitis and other inflammatory skin diseases.
Aspen和Bambusa各自在IPO中发行938万股，发行价区间为每股15美元至17美元。
Aspen and Bambusa are each marketing 9.38 million shares in their IPOs priced between $15 and $17 apiece.
Leerink Partners、UBS投资银行、Piper Sandler、Stifel和Oppenheimer负责承销Aspen的发行，而BofA Securities、Evercore ISI、UBS投资银行和Cantor负责处理Bambusa的发行。
Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer are underwriting Aspen's offering, while BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are handling Bambusa's.
Aspen将以“ASPE”为代码在纳斯达克上市，Bambusa将以“BBTX”为代码上市。
Aspen will list on the Nasdaq under the symbol "ASPE," and Bambusa under "BBTX."